DMW – Klinischer Fortschritt, Table of Contents Dtsch Med Wochenschr 2014; 139(40): 1993-1996DOI: 10.1055/s-0034-1370285 Hämatologie und Onkologie | Review article Hämatologie © Georg Thieme Verlag KG Stuttgart · New York Thrombotische Mikroangiopathien Thrombotic microangiopathies M. Starck 1 Klinik für Hämatologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin, Klinikum Schwabing, München , C.-M. Wendtner 1 Klinik für Hämatologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin, Klinikum Schwabing, München › Author Affiliations Recommend Article Abstract Buy Article Schlüsselwörter Schlüsselwörterthrombotische Mikroangiopathie - thrombotisch-thrombozytopenische Purpura - hämolytisch-urämisches Syndrom - Plasmapherese - Rituximab - Eculizumab Keywords Keywordsthrombotic microangiopathy - thrombotic thrombocytopenic purpura - hemolytic uremic syndrome - plasma exchange - rituximab - eculizumab Full Text References Literatur 1 Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2013; 33: 27-45 2 Crawley JTB, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology Am Soc Hematol Educ Program 2013; 2013: 292-299 3 Hie M, Gay J, Galicier L et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura: experience of the French Thrombotic Microangiopathies Reference Center. Blood 2014; 124: 204-210 4 Holz JB. The TITAN trial – assessing the efficacy and safety of an anti-von Willebrand factor nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci 2012; 46: 343-346 5 Karpman D. Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed. Nephrol Dial Transplant 2012; 27: 3669-3674 6 Knöbl P. Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. Semin Thromb Hemost 2014; 40: 493-502 7 Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med 2013; 368: 2169-2181 8 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687 9 Plaimauer B, Kremer Hovinga JA, Juno C et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011; 9: 936-944 10 Roumenina LT, Loirat C, Dragon-Durey MA et al. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011; 365: 8-26 11 Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol 2014; 164: 759-766 12 Scully M, Hunt BJ, Benjamin S et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-335 13 Starck M, Wendtner CM. Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy. Br J Haematol 2014; 164: 894-896 14 Tsai HM. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med 2013; 126: 200-209 15 Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657
